Ophthalmology. Retina · 2025
Late-Onset Retinoblastoma: Clinical and Genetic Features in Children Presenting Over 5 Years Old.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Evans William I, Thompson Barrett N, King Benjamin A, McGee Rose B, Groshek Cassi-Jo, Qaddoumi Ibrahim, Rodriguez-Galindo Carlos, Brennan Rachel C, Wilson Matthew W
Аннотация
OBJECTIVE: To define the clinical features and genetics of children with retinoblastoma diagnosed at ≥5 years of age.
DESIGN: Retrospective review.
SUBJECTS: Children ≥5 years of age treated for retinoblastoma at a single institution between January 1999 and January 2022.
METHODS: A chart review including demographics, genetic testing, laterality, presenting signs and symptoms, initial diagnosis if not retinoblastoma, and procedures performed on affected eyes before diagnosis of retinoblastoma.
MAIN OUTCOME MEASURES: Tumor classification, treatments and outcomes, and genetic data on tumors.
RESULTS: Of the 529 retinoblastoma patients identified, 25 (4.7%) were diagnosed at ≥5 years of age (median age 6.0 years, range 5.1-11.3 years). Most patients (24 of 25, 96%) presented with unilateral disease. Nine of 25 (36%) were misdiagnosed before presentation. Pathogenic RB1 germline mutations were identified in 6 of the 24 (25%) patients who underwent testing; 1 child had a positive family history. Further evaluation in 6 tumors (from 6 patients) identified hypermethylation of the RB1 gene promoter in 2 patients.
CONCLUSIONS: Older children with retinoblastoma are commonly misdiagnosed before presentation. Germline predisposition to retinoblastoma was more common than anticipated for patients with late-onset unilateral disease. This may have important implications for treatment and prognosis.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
DESIGN: Retrospective review.
SUBJECTS: Children ≥5 years of age treated for retinoblastoma at a single institution between January 1999 and January 2022.
METHODS: A chart review including demographics, genetic testing, laterality, presenting signs and symptoms, initial diagnosis if not retinoblastoma, and procedures performed on affected eyes before diagnosis of retinoblastoma.
MAIN OUTCOME MEASURES: Tumor classification, treatments and outcomes, and genetic data on tumors.
RESULTS: Of the 529 retinoblastoma patients identified, 25 (4.7%) were diagnosed at ≥5 years of age (median age 6.0 years, range 5.1-11.3 years). Most patients (24 of 25, 96%) presented with unilateral disease. Nine of 25 (36%) were misdiagnosed before presentation. Pathogenic RB1 germline mutations were identified in 6 of the 24 (25%) patients who underwent testing; 1 child had a positive family history. Further evaluation in 6 tumors (from 6 patients) identified hypermethylation of the RB1 gene promoter in 2 patients.
CONCLUSIONS: Older children with retinoblastoma are commonly misdiagnosed before presentation. Germline predisposition to retinoblastoma was more common than anticipated for patients with late-onset unilateral disease. This may have important implications for treatment and prognosis.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.